All Updates

All Updates

icon
Filter
Funding
METiS Therapeutics raises USD 64 million in Series A-2 financing
AI Drug Discovery
Apr 5, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Apr 5, 2022

METiS Therapeutics raises USD 64 million in Series A-2 financing

Funding

<ul><li> Massachusetts-based AI drug discovery company METiS Therapeutics has raised USD 64 million in a Series A-2 funding round, bringing the total Series A funds to USD 150 million (the previous Series A round closed in December 2021 ). Both rounds were led by PICC Capital and China Life Private Equity Investment with participation from Sequoia Capital China, Lightspeed China Partners, and other investors.</ul>

  • The proceeds will be directed toward accelerating the company’s R&D efforts including the development of its AI drug discovery and delivery platform “AiTEM,” and advancing a few of its drug candidates into clinical trials in early 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.